Zurn said Pfizer hadn't shown that Metsera's board hadn't acted in good faith when evaluating the Novo Nordisk offer, leaving her no basis to conclude that exiting the Pfizer deal would be a wrongful ...
Good day, everyone, and welcome to Pfizer Pflash, a spotlight on the PD-1 VEGF bispecific PF-4404 clinical development strategy. Today's call is being recorded. At this time, I would like to turn the ...
Pfizer has secured a $10 billion acquisition of obesity drug developer Metsera, outbidding rival Novo Nordisk in a heated contest for the biotech firm. The deal, finalized after Novo Nordisk withdrew ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results